vs
Apellis Pharmaceuticals, Inc.（APLS）与FIRST FINANCIAL BANCORP（FFBC）财务数据对比。点击上方公司名可切换其他公司
FIRST FINANCIAL BANCORP的季度营收约是Apellis Pharmaceuticals, Inc.的1.4倍（$271.5M vs $199.9M），FIRST FINANCIAL BANCORP净利率更高（27.4% vs -29.5%，领先56.9%），过去两年FIRST FINANCIAL BANCORP的营收复合增速更高（12.4% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
第一金融银行集团是总部位于美国俄亥俄州辛辛那提的区域性银行，运营中心设于辛辛那提北郊斯普林代尔及印第安纳州格林斯堡。该行成立于1863年，拥有美国第六悠久的国家银行牌照，在俄亥俄、印第安纳、肯塔基、伊利诺伊四州共设有131个营业网点，2009年9月曾在政府协助下收购欧文金融公司及其子公司。
APLS vs FFBC — 直观对比
营收规模更大
FFBC
是对方的1.4倍
$199.9M
净利率更高
FFBC
高出56.9%
-29.5%
两年增速更快
FFBC
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $271.5M |
| 净利润 | $-59.0M | $74.4M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 27.4% |
| 营收同比 | -5.9% | — |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $0.71 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSFFBC
| Q1 26 | — | $271.5M | ||
| Q4 25 | $199.9M | $238.8M | ||
| Q3 25 | $458.6M | $234.0M | ||
| Q2 25 | $178.5M | $226.3M | ||
| Q1 25 | $166.8M | $200.4M | ||
| Q4 24 | $212.5M | $224.3M | ||
| Q3 24 | $196.8M | $201.3M | ||
| Q2 24 | $199.7M | $214.8M |
净利润APLSFFBC
| Q1 26 | — | $74.4M | ||
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $71.9M | ||
| Q2 25 | $-42.2M | $70.0M | ||
| Q1 25 | $-92.2M | $51.3M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $52.5M | ||
| Q2 24 | $-37.7M | $60.8M |
营业利润率APLSFFBC
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | 38.7% | ||
| Q2 25 | -18.6% | 38.8% | ||
| Q1 25 | -50.0% | 31.7% | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | 32.2% | ||
| Q2 24 | -14.7% | 34.8% |
净利率APLSFFBC
| Q1 26 | — | 27.4% | ||
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 30.7% | ||
| Q2 25 | -23.6% | 30.9% | ||
| Q1 25 | -55.3% | 25.6% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | 26.1% | ||
| Q2 24 | -18.9% | 28.3% |
每股收益（稀释后）APLSFFBC
| Q1 26 | — | $0.71 | ||
| Q4 25 | $-0.40 | $0.64 | ||
| Q3 25 | $1.67 | $0.75 | ||
| Q2 25 | $-0.33 | $0.73 | ||
| Q1 25 | $-0.74 | $0.54 | ||
| Q4 24 | $-0.30 | $0.68 | ||
| Q3 24 | $-0.46 | $0.55 | ||
| Q2 24 | $-0.30 | $0.64 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | $13.1M |
| 股东权益账面价值 | $370.1M | $2.9B |
| 总资产 | $1.1B | $22.5B |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资APLSFFBC
| Q1 26 | — | — | ||
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — |
总债务APLSFFBC
| Q1 26 | — | $13.1M | ||
| Q4 25 | — | $514.1M | ||
| Q3 25 | — | $221.8M | ||
| Q2 25 | — | $345.0M | ||
| Q1 25 | — | $345.9M | ||
| Q4 24 | — | $347.5M | ||
| Q3 24 | — | $344.1M | ||
| Q2 24 | — | $338.6M |
股东权益APLSFFBC
| Q1 26 | — | $2.9B | ||
| Q4 25 | $370.1M | $2.8B | ||
| Q3 25 | $401.2M | $2.6B | ||
| Q2 25 | $156.3M | $2.6B | ||
| Q1 25 | $164.2M | $2.5B | ||
| Q4 24 | $228.5M | $2.4B | ||
| Q3 24 | $237.1M | $2.5B | ||
| Q2 24 | $264.3M | $2.3B |
总资产APLSFFBC
| Q1 26 | — | $22.5B | ||
| Q4 25 | $1.1B | $21.1B | ||
| Q3 25 | $1.1B | $18.6B | ||
| Q2 25 | $821.4M | $18.6B | ||
| Q1 25 | $807.3M | $18.5B | ||
| Q4 24 | $885.1M | $18.6B | ||
| Q3 24 | $901.9M | $18.1B | ||
| Q2 24 | $904.5M | $18.2B |
负债/权益比APLSFFBC
| Q1 26 | — | 0.00× | ||
| Q4 25 | — | 0.19× | ||
| Q3 25 | — | 0.08× | ||
| Q2 25 | — | 0.13× | ||
| Q1 25 | — | 0.14× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSFFBC
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $337.9M | ||
| Q3 25 | $108.5M | $89.8M | ||
| Q2 25 | $4.4M | $69.8M | ||
| Q1 25 | $-53.4M | $56.1M | ||
| Q4 24 | $19.4M | $262.2M | ||
| Q3 24 | $34.1M | $88.1M | ||
| Q2 24 | $-8.3M | $68.1M |
自由现金流APLSFFBC
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $317.1M | ||
| Q3 25 | $108.3M | $85.8M | ||
| Q2 25 | $4.4M | $64.8M | ||
| Q1 25 | $-53.4M | $52.4M | ||
| Q4 24 | $19.3M | $241.1M | ||
| Q3 24 | — | $84.4M | ||
| Q2 24 | $-8.4M | $64.8M |
自由现金流率APLSFFBC
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 132.8% | ||
| Q3 25 | 23.6% | 36.7% | ||
| Q2 25 | 2.5% | 28.6% | ||
| Q1 25 | -32.0% | 26.1% | ||
| Q4 24 | 9.1% | 107.5% | ||
| Q3 24 | — | 42.0% | ||
| Q2 24 | -4.2% | 30.2% |
资本支出强度APLSFFBC
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 8.7% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.0% | 2.2% | ||
| Q1 25 | 0.0% | 1.9% | ||
| Q4 24 | 0.0% | 9.4% | ||
| Q3 24 | 0.0% | 1.8% | ||
| Q2 24 | 0.0% | 1.5% |
现金转化率APLSFFBC
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 1.25× | ||
| Q2 25 | — | 1.00× | ||
| Q1 25 | — | 1.09× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.68× | ||
| Q2 24 | — | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
FFBC
| Net Interest Income | $189.6M | 70% |
| Noninterest Income | $81.9M | 30% |
